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ense.Abstract Introduction: Alveolar hemorrhage (AH) is a rare, but serious manifestation of SLE. It
may occur early or late in disease evolution. Extrapulmonary disease may be minimal and may be
masked in patients who are already receiving immunosuppressants for other symptoms of SLE. The
capacity of AH to occur and recur despite ongoing immunosuppressive therapy is emphasized.
Aim of the work: Reporting our experience with alveolar hemorrhage in patients with systemic
lupus erythematosus.
Patients and methods: Records of SLE patients admitted between years 2000 and 2008 were
reviewed. Seven patients with SLE admitted with nine episodes of AH were found. For all study
subjects, the pertinent demographic, clinical, laboratory, histologic, therapeutic and outcome data
were abstracted and chest X-ray reviewed. The disease activity was assessed using SLEDAI.
Results and Conclusion: The seven patients were females. Their age ranged from 17 to 35 years and
disease duration ranged from 4 to 48 months. AH occurred within 4 months of SLE onset in two
patients. All patients presented with hemoptysis, new pulmonary inﬁltrates and hemoglobin drop.
Glomerulonephritis was the most common extrapulmonary SLE manifestation (85%). Initial treat-
ment included IV methylprednisolone in all cases (100%), with cyclophosphamide in four episodes.
Plasmapheresis (one session) was done in only one episode. Survival rate was 14%.hoo.com (G.A. Mahmoud),
h), dr_2mkamel@yahoo.com
ail.com (R.A. Soliman).
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2 G.A. Mahmoud et al.Conclusion: Alveolar hemorrhage is a rare but lethal complication of SLE and represents a remark-
able challenge. It should be diagnosed promptly with falling red cell indices and new inﬁltrates on
chest radiograph. It occurs in vicinity of active disease. Lupus nephritis is most associated manifes-
tation. Alveolar hemorrhages frequently recur despite ongoing immunosuppressant therapy. Early
treatment with intra venous (IV) pulse methylprednisolone and IV cyclophosphamide should be
instituted for a better outcome.
 2011 Egyptian Society for Joint Diseases and Arthritis. Production and hosting by Elsevier B.V.
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Systemic lupus erythematosus (SLE) is a chronic systemic dis-
ease which can often involve many organs systems [1]. The
lung is an organ preferentially affected in SLE, and shows var-
ious symptoms, including pleuritis, diffuse interstitial lung dis-
ease, pulmonary embolism, pulmonary hypertension and
pulmonary hemorrhage [2]. The noninfectious pleuropulmo-
nary complications of SLE occur at some point during the dis-
ease course in 50–70% of affected individuals. Although these
are frequent complications and often responsible for serious
morbidity, they account for a very low mortality rate (<4%)
[3].
Alveolar hemorrhage (AH) is a potentially catastrophic and
often lethal pulmonary complication of SLE. Among the rheu-
matologic diseases, AH most frequently occurs in patients with
SLE and systemic vasculitis. It is an uncommon complication
with reported frequencies ranging from 1% to 5.4% of lupus
cohorts [4]. It accounts for 1.5–3.7% of hospital admission
due to SLE. However, it is often serious; requiring early, inten-
sive therapy and is associated with high mortality ranging from
23% to 92% [5].
In this article we summarize the course of seven consecutive
patients admitted to the Rheumatology and Rehabilitation
and Critical Care Departments, Cairo University hospital be-
tween years 2000 and 2008. They suffered from nine episodes
of SLE-associated alveolar hemorrhage. We compare our
experience with reports from the medical literature.
2. Patients and methods
A retrospective chart review was carried out for all admissions
of patients diagnosed as SLE from years 2000 to 2008. To be
included, patients had to fulﬁll the revised criteria of the Amer-
ican Rheumatism Association for the diagnosis of SLE [6]. The
diagnostic criteria for diffuse alveolar hemorrhage were at least
three of the following: pulmonary symptoms, new inﬁltrates on
chest radiographs, a drop of hemoglobin of at least 1.5 g/dl,
and a bloody return on bronchoalveolar lavage with hemosid-
erin-containing macrophage. Severe coagulopathy (INR>
3.5), acute pulmonary edema, or pulmonary embolism was ex-
cluded [7].
Onset of AH was deﬁned as the earliest date when pulmon-
ary symptoms (acute or recent development of dyspnea, hem-
optysis) correlated with objective clinical ﬁndings (chest
radiographs demonstrating new pulmonary inﬁltrates or a
drop in hemoglobin level) [5].
Duration of AH was based on the time between onset of
AH to the ﬁrst of two consecutive days when the patient’s
hematocrit (obtained at least daily) remained stable without
need of transfusion [5].For all study subjects a retrospective chart was done
reviewing the following data:
(1) Demographic characteristics.
(2) Clinical data of the patient prior to episode of AH were
reviewed including: constitutional manifestations, car-
diopulmonary and thrombo-embolic manifestations,
cutaneous, musculoskeletal, neuropsychatric, gastroin-
testinal and urogenital manifestations. Presence of acute
or chronic renal failure was reported. Acute renal failure
was deﬁned as serum creatinine level exceeding 3.2 mg/
dl and chronic renal failure as a 2-fold creatinine rise
in [8]. SLE disease activity index (SLEDAI) [9] was
reported 3 months prior to attack.
(3) Laboratory investigations done 6 months and 1 month
prior to attack of AH were reviewed including: autoim-
mune proﬁles in the form of ANA, anti-ds DNA and
anticardiolipin antibodies, complete blood counts,
erythrocyte sedimentation rate (ESR), C-reactive pro-
tein (CRP), serum complement (C3, C4), coagulation
proﬁle, liver and kidney functions. Complete urine-anal-
ysis and 24 h urinary protein: nephrotic syndrome was
deﬁned as daily total urinary protein greater than 3 g
and clinical nephritis was deﬁned as proteinuria
(>0.5 g/24 h), microscopic hematuria or cellular cast [7].
(4) Radiographic investigations done including (chest X-ray
and CT) prior and during the attack of AH were
reviewed.
(5) Histologic studies including renal biopsies performed to
the patient classiﬁed according to WHO criteria were
reviewed.
(6) Treatment of SLE prior to episode of AH and treatment
of AH attack were reviewed including dose and duration
of: corticosteroids, immunosuppressants, and other
treatment modalities.
(7) Presentation of AH in the form of fever, cough, dysp-
nea, chest pain, hemoptysis, hemoglobin drop, new
radiographic inﬁltrates together with associated extra-
pulmonary manifestations was reviewed.
(8) Outcome data: survival was deﬁned as the resolution of
all symptoms related to AH and discharge in a stable
condition [5].
3. Results
Throughout the time period from 2000 to 2008, seven patients
with nine episodes of pulmonary hemorrhage met the inclusion
criteria in the study. These seven patients represent 1.34% (7 of
522) of patients with SLE admitted to Rheumatology and Crit-
ical Care Departments with a diagnosis of SLE.
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orrhage was (17–35 years), mean ± SD: 23 ± 6.03. The range
of age of the patients at SLE onset was (16–35 years),
mean ± SD: 21 ± 6.72. Alveolar hemorrhage occurred within
4 months of SLE diagnosis in two cases and after 24 months in
two cases. AH also occurred after 28, 36, 48 months in the
other three cases. The range of SLE disease duration was (4–
48 months), mean ± SD: 2 ± 16 (Table 1).
The most common SLE manifestations prior to the ﬁrst at-
tack of alveolar hemorrhage were hematologic and musculo-
skeletal manifestations. Hematologic manifestations were
detected in all of the seven cases (100%) in the form of anemia
in all cases and leukopenia in one case (14.2%). Thrombocyto-
penia could not be detected in any of the cases. Musculoskel-
etal manifestations in the form of arthralgia and arthritis were
also present in all of the seven cases (100%).
The second most common SLE disease manifestations
occurring in six out of seven cases (85.7%) were kidney affec-
tion and skin manifestations. Mucocutaneous manifestations
occurred, in the form of malar rash, photosensitivity, oral
ulcers and alopecia.
Serositis in the form of pleuritis and pericarditis with or
without effusion was present in ﬁve out of seven cases
(71.4%). Pleuritis occurred in four cases and pericarditis with
effusion occurred in only one case.
Constitutional symptoms also occurred in four out of seven
cases (57.2%) in the form of fatigue, fever and weight loss.
CNS manifestations were present in three cases (42.2%) in
the form of recent cerebrovascular accident, seizure, severe
headache not relieved by analgesics and increased intracranial
pressure manifested by repeated vomiting and papilledema on
fundus examination (Table 2).
Renal involvement in the form of clinical nephritis, nephro-
tic syndrome, or acute renal failure occurred in six out of seven
cases of SLE representing 85.7% being the 2nd most commonTable 1 Patients’ demographics in SLE-associated AH.
Case no. Sex Age at AH
(years)
Disease duration
(months)
Age at SLE
onset (years)
Case 1 Female 17 4 17
Case 2 Female 35 4 35
Case 3 Female 23 24 21
Case 4 Female 20 48 16
Case 5 Female 26 28 24
Case 6 Female 19 24 17
Case 7 Female 21 36 18
Table 2 SLE manifestations prior to AH.
Case no. Heamatologic Arthritis Kidney
Case 1 + + +
Case 2 + + +
Case 3 + + +
Case 4 + + +
Case 5 + + +
Case 6 + + +
Case 7 + + 
100% 100% 85.7%disease manifestation after the hematologic and musculoskele-
tal manifestations.
The six cases had undergone renal biopsy and pathological
classiﬁcation according to world health organization (WHO)
was done. Four cases had class 4 (diffuse proliferative glomer-
ulonephritis), one case suffered from class 5 (membranous glo-
merulonephritis) and the last one suffered from class 6
(sclerosing glomerulonephritis).
Six out of seven cases (85.7%) had lupus nephritis. Two out
of six cases (33.3%) had nephrotic syndrome and the all six
cases were suffering from hypoalbuminemia. The mean uri-
nary protein in 24 h level was 2.65 (ranged from 1.4 to
3.9) g/24 h while the mean serum albumin level was 2.7 (ranged
from 2 to 3.2) g/dl in the last 3 months.
Acute renal failure requiring hemodialysis was reported in
three out of six cases (50%) (1–2 sessions) and no one required
regular dialysis. The mean serum creatinine level in the
3 months previous to the attack was 4.2 (ranged from 1.03 to
7.4) mg/dl. One case (16.6%) had normal serum creatinine
and the other ﬁve cases (83.3%) had a variable degree of ele-
vated serum creatinine. Hypertension was present in four out
of six cases (66.6%) where antihypertensive drugs were re-
ceived (Table 3).
Alveolar hemorrhage occurred in six out of seven cases
(85.7%) already receiving treatment for manifestations of
SLE. Five out of seven cases (71.4%) were receiving oral cor-
ticosteroids (prednisolone, dose range, 10–40 mg/day), four
out of seven cases (57.1%) were receiving monthly IV pulse
methylprednisolone ranging 500–1000 mg for three consecu-
tive days and three out of seven cases (42.8%) received cyclo-
phosphamide pulse (ranging 750–1000 mg/m2) for lupus
nephritis. The 4th case received (800 mg/m2) cyclophospha-
mide in the last month only. Azathioprine (100 mg daily)
was used in four out of seven cases (57.2%) (nos. 2, 3, 4 and
5) and hydroxychloroquine (400 mg/day) was also used in four
cases (57.2%). Other treatment was given to all cases which in-
clude (antihypertensive and antibiotics).
Immunosuppressive therapy within 1 week before AH had
been reported in ﬁve out of seven cases (71.4%). One course
of IV pulse methylprednisolone (1 g for 1–3 consecutive days)
was administered within 1 week prior to pulmonary hemor-
rhage. Three cases received the pulse due to active lupus
nephritis and the other two cases were due to CNS affection.
Only two cases were receiving one course of parenteral pulse
cyclophosphamide therapy (500–800 mg/m2) within 1 week
prior to pulmonary hemorrhage (Table 4).
Regarding the symptoms and signs of pulmonary hemor-
rhage, hemoptysis and hemoglobin drop were observed in all
episodes (100%). Hemoptysis was initially present as bloodSkin Serositis Constitutional CNS
 +  +
+ + + 
+ + + 
+ + + +
+   
+   +
+ + + 
85.7% 71.4% 57.2% 42.8%
Table 3 Renal affection in SLE.
Case no. Biopsy Ptn/24 h (g) Albumin (g/dl) Creatinine (mg/dl) HTN ARF Nephrotic
Case 1 Class 4 3.9 2.2 2.4   +
Case 2 Class 5 3 2 3.1 +  
Case 3 Class 4 2 3.1 1.03   
Case 4 Class 6 1.4 2.8 6.6 + + 
Case 5 Class 4 3.6 3.1 4.5 + + +
Case 6 Class 4 2 3.2 7.4 + + 
Abbreviations: HTN= hypertension; ARF= acute renal failure.
Table 4 SLE therapy prior to AH.
Case no. Pred. (mg/day) Pulse steroid Pulse CYC AZT (mg/day) HXQ (mg/day) Others
Case 1 –   – – +
Case 2 10   100 – +
Case 3 10–25 +  100 400 +
Case 4 15–40 + + 100 400 +
Case 5 20–40 + + 100 – +
Case 6 30–40 + + – 400 +
Case 7 –   – 400 +
Abbreviations: Pred. = prednisolone; HXQ= hydroxychloroquine.
4 G.A. Mahmoud et al.tinged sputum and rapidly turns into frank hemoptysis in eight
episodes and only one episode (1st episode of case no. 1)
showed frank hemoptysis at the beginning of the attack.
Dyspnea and cough were observed in eight episodes
(88.8%). The onset of dyspnea was mild in one episode (case
no. 4) which rapidly became severe while the other episodes
suffered from abrupt onset of severe dyspnea, tachypnea and
respiratory distress which required assisted ventilation. Tem-
perature elevation more than 38 C was noted in six episodes
(66.6%).
Chest radiograph was performed in all episodes and it re-
vealed newly encountered alveolar inﬁltrates in all episodes
(100%) of AH. The most common radiographic pattern was
bilateral diffuse inﬁltrates in eight out of nine episodes
(88.8%). Unilateral densities which could be easily mistaken
for lobar pneumonia were seen in one episode (case no. 4).
Bilateral pleural effusion was detected in only one case. HRCT
chest performed in four out of nine episodes (44.4%) revealed
diffuse alveolar inﬁltrates which conﬁrms the diagnosis
(Table 5) (see Figs. 1 and 2).Table 5 Clinical manifestations of nine episodes of DAH.
Episode no. Hemoptysis Dyspnea Cough
Case 1 1 + + +
2 + + +
Case 2 1 + + +
Case 3 1 + + +
Case 4 1 + + +
Case 5 1 + + +
Case 6 1 +  +
2 + + +
Case 7 1 + + Extrapulmonary manifestations of disease during attack of
AH are summarized in Table 6. In addition to AH, other sys-
temic involvement had been reported including renal, CNS,
hematologic and joint affections. Active lupus nephritis was
the most common extrapulmonary manifestations occurring
in conjunction with AH attack being present in eight out of
nine episodes (88.8%). Neuropsychiatric manifestations
including seizure and psychological disturbance in the form
of (psychosis, hallucinations, change in mode, depression) oc-
curred within 1 week of AH attack in ﬁve out of nine episodes
(55.5%). Convulsions were the most common among the CNS
manifestations as it occurred in three episodes. The ﬁts pre-
ceded AH attack by 1–2 days in cases and followed the onset
of the attack in one case. Psychological disturbance preceded
AH episodes 3–5 days in two cases. Hematologic manifesta-
tions in the form of leukopenia (<4 · 103) were present in
two out of nine episodes (22.2%) at the time of AH. Neither
thrombocytopenia nor autoimmune hemolytic anemia could
be detected in any case at that time. Arthritis was present in
one out of nine episodes (11.1%).Fever > 38 C Hbﬂ X-ray inﬁltrate CT inﬁltrate
+ + + /
+ + + +
 + + +
+ + + /
+ + + /
 + + +
 + + /
+ + + /
+ + + +
Figure 1 Chest X-rays of second episode of case no. 1. (A) Mild bilateral inﬁltrates at the onset 1st day of attack. (B) Bilateral ill deﬁned
diffuse opacities mostly involving the right lower and left upper zones at the 1st day of attach during frank hemoptysis. (C) Partial
resolution of the inﬁltrates following 5th dose of pulse steroid therapy and pulse cyclophosphamide at 6th day of attack. (D) Bilateral ill
deﬁned diffuse opacities mostly involving the whole lungs at 10th day of attack before death of the patient.
Figure 2 HRCT chest of case no. 5. (A and B) Area of hyperdensity on both lung ﬁelds (suggestive of hemorrhage) at the 1st day of
attack. (C and D) Complete resolution of both lungs on the 4th day of attack following 3 days dose of pulse steroid therapy (1 g/day).
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Table 7. The spectrum of SLE patients’ characteristics varied
greatly. The SLE disease activity index was diverse (SLEDAI
range: 17–36). Severe disease activity according to SLEDAI
(grading: 21–45) was reported in six out of seven cases(85.7%) while moderate disease activity according to SLEDAI
(grading: 11–20) was reported in only one out of seven cases
(14.3%).
Laboratory ﬁndings at the time of diffuse alveolar hemor-
rhage (DAH) are summarized in Table 8. A drop in hemoglobin
Table 6 Extrapulmonary manifestations of SLE during attacks of AH.
Case no. Episode Kidney CNS Hematologic Arthritis
Leukopenia Thrombocytopenia AIHA
Case 1 1 +     
2 +     
Case 2 1 + +    +
Case 3 1 + + +   
Case 4 1 +     
Case 5 1 + + +   
Case 6 1 +     
2 + +    
Case 7 1  +    
Abbreviations: AIHA= autoimmune hemolytic anemia.
Table 7 SLEDAI of seven SLE cases suffered from AH.
Case no. SLEDAI
Case 1 27
Case 2 26
Case 3 24
Case 4 25
Case 5 17
Case 6 36
Case 7 25
6 G.A. Mahmoud et al.level was detected within 48 h from onset of PH in all cases
(100%). Hemoglobin drop ranged from 1.5 to 3.2 g/dl (mean
2.3). Platelet count range was 180,000–300,000 cells/mm3 (mean
249,770). INR range was 1–1.6 (mean 1.17). No coagulopathy
or critical thrombocytopenia (<50,000 cells/mm3) could be
detected in any case and anticoagulation therapy was not re-
ported. Anticardiolipin antibody was negative in all cases
(100%). Creatinine level range in seven out of nine episodes
was 3.7–5.7 mg/dl (mean 4.9). Anti-double stranded DNA pos-
itivity was found in all episodes (100%) and hypocomplemente-
mia was reported in eight out of nine episodes (85.7%).
Treatment of DAH is summarized in Table 9. All episodes
(100%) were treated initially with intravenous methylprednis-
olone, the doses ranging from 500 to 1000 mg/day forTable 8 Laboratory ﬁndings in seven cases during attacks of AH.
Case no. Epi. no. Hbﬂ in 48 h (g/dl) Platelet (cells/mm3) INR
Case 1 1 3 267 · 103 1.2
2 3.2 300 · 103 1.3
Case 2 1 1.8 184 · 103 1.4
Case 3 1 1.8 296 · 103 1.1
Case 4 1 1.5 250 · 103 1
Case 5 1 2.5 256 · 103 1
Case 6 1 1.5 285 · 103 1.6
2 3.2 230 · 103 1
Case 7 1 2 180 · 103 1
Abbreviations: Hbﬂ= hemoglobin drop; INR= international normalize
DNA= antibodies to double stranded DNA.2–5 days. Cyclophosphamide was employed in four episodes
(44.4%), it was initially given intravenously as a single dose
(range, 500–800 mg/m2) after steroid pulse. Plasmapheresis
was employed in one case (14.3%) as one session on the 4th
day of attack and no more sessions as the patient died the next
day. Broad spectrum antibiotics was started empirically while
cultures were pending in all episodes (100%) and proper isola-
tion of the patients was done to avoid infection. Dialysis due to
acute renal failure was done in ﬁve episodes (55.5%). Perito-
neal dialysis in one case and hemodialysis in four episodes
and only one episode required regular dialysis after the attack.
All cases required intensive care where assisted ventilation was
employed in the form of mechanical ventilation in seven epi-
sodes (77.7%) and oxygen mask in two episodes (22.2%).
Outcome of DAH is summarized in Table 10. Recurrence
of AH occurred despite aggressive therapy. Recurrent episodes
were noted in two cases during follow up period of 1 month.
The interval between the two episodes was 21 days in both
cases. One case died during 2nd attack as she developed hy-
poxia, hypercapnia and respiratory arrest while the other case
survived the 2nd attack and was discharged from ICU.
Death during admission in ICU has been reported in six out
of nine episodes (66.6%). The cause of death was due to respi-
ratory failure. The overall mortality rate was 66.6% (6/9 epi-
sodes). On a per-patient basis the mortality was 85.7% (6/7
cases).aCL Low C3 and C4 Anti-ds DNA Creatinine (mg/dl)
 + + /
 + + 3.7
 + + 4.2
 + + 5.1
 + + 5.7
 + + 4.8
 + + 5.3
 + + 5.7
  + /
d ratio; aCL = anti-cardiolipin antibodies; C = complement; anti-ds
Table 9 Treatment of DAH.
Case no. Episode Cs CYC PP AB D V
Case 1 1 + +  + HD MV
2 + +  + HD MV
Case 2 1 + +  + – MV
Case 3 1 +  + + – MV
Case 4 1 +   + PD MV
Case 5 1 +   + – MV
Case 6 1 + +  + HD O2
2 +   + HD O2
Case 7 1 +   +  MV
Abbreviations: Cs = corticosteroids; CYC= cyclophosphamide; PP = plasmapheresis; AB = antibiotics; D = dialysis; HD= hemodialysis;
PD= peritoneal dialysis; V = ventilation; MV=mechanical ventilation.
Table 10 Outcome of DAH.
Case no. Episode no. Outcome
Case 1 1 Alive
2 Died
Case 2 1 Died
Case 3 1 Died
Case 4 1 Died
Case 5 1 Died
Case 6 1 Alive
2 Alive
Case 7 1 Died
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SLE is an autoimmune disease characterized by disturbances
in innate and adaptive immune mechanisms. Multiple systems
and organs may be involved. Pulmonary disease is a common
manifestation of SLE and is reported to occur in over half of
the patients throughout the course of their disease [10].
Pulmonary disease in SLE can be extremely diverse, encom-
passing abnormalities such as pleuritis with pleural effusions,
acute lupus pneumonitis, diffuse interstitial lung disease, pul-
monary hypertension, pulmonary embolism, diaphragmatic
abnormalities, atelectasis and pulmonary alveolar hemorrhage
[11–13]. The latter is the most devastating pulmonary compli-
cation which was ﬁrst described by Osler in 1904 [4].
This retrospective study was designed to evaluate the SLE
patients with AH in Rheumatology and Rehabilitation, Criti-
cal Care Departments, Cairo University.
DAH is a rare fatal complication with reported frequency
ranging from 1% to 5.4% of Lupus cohorts [14,15]. It ac-
counts for 1.5–3.7% of hospital admissions due to SLE
[16,17]. A lower incidence of DAH (0.52%) was reported by
Chang et al. [7]. In the current study, DAH accounted for
1.3% of SLE cohorts. However, in autopsy series, alveolar
hemorrhage, appearing as either focal collection of red blood
cells or more diffuse involvement, has been reported to occur
in as many as 66% of cases of SLE [18].
All patients in the current study were females. However, fe-
male prevalence in literature review was 79%. Similar to most
reports, most of our patients were young (mean age was23 years). The mean age in the majority of published reports
ranged between 23 and 37.8 years [5,15–17,19].
AH occurred early in the course of disease. The mean dis-
ease duration was 2 years. In most patients with pulmonary
hemorrhage (PH), the diagnosis of SLE has already been
established; however, PH as initial manifestation of SLE is also
seen. In most studies, the mean duration of SLE ranged from
1.8 to 4.5 years [5,14–17]. Only one previous study [20] re-
ported PH occurring after a mean duration of 14.1 years of
SLE. Although cases of AH as a presenting symptom were re-
ported in some series [5,21,22], we did not report any cases
with AH at disease onset.
The onset of AH is abrupt and the symptoms are acute usu-
ally developing over hours to several days. This is the case in
our study and other series [15–17,23].
Presentation of AH with the ‘‘classical triad’’ of hemopty-
sis, abrupt fall in hemoglobin level, and new pulmonary inﬁl-
trates were present in all cases of the present work.
However, this triad was not uniformly seen in other series
[16,17,24,25].
In published literature, presentation with hemoptysis is re-
ported with a frequency of 25–100%, compared to 100% in
ours [16,25]. Zamora et al. [17] reported hemoptysis in only
42% of the episodes at the time of admission but appeared
at some point during the hospital stay in all episodes.
New pulmonary inﬁltrates (published frequency 83–100%,
compared to 100% in our study) accompanied by worsening
or new anemia (published frequency 75–100%, 100% in our
study) appear to be more sensitive clinical signs.
The absence of hemoptysis is not unique for AH in SLE,
having been reported for other etiologies of DAH [26]. In this
situation, diffuse pulmonary inﬁltrates, a falling hematocrit
and a sequential hemorrhagic bronchoalveolar lavage point
to diagnosis. Although most SLE patients are too ill to under-
go this evaluation, a single breath diffusing capacity for carbon
monoxide will be elevated, reﬂecting the increased availability
of hemoglobin within the distal airspaces [27]. However, DLco
assessment was not reported in our series. This was attributed
to the patients’ poor and unstable condition.
Acute dyspnea, cough, rales, chest pain, dyspnea and fever
>38 C are frequently present, leading to diagnostic confusion
with bacterial and opportunistic pulmonary infections.
Dyspnea was reported in 89% of our studied cases. How-
ever, Liu et al. [15] and Santos Ocampo et al. [5] reported
8 G.A. Mahmoud et al.dyspnea in all cases. Again, fever >38 C was present in 67%
of our studied episodes which was similar to those reported by
many authors [5,14,15].
The recurrent nature of AH was of concern, and this
frequently occurred without warning. The occurrence of AH
despite ongoing treatment with signiﬁcant dose of immunosup-
pressive drugs must be noted [5]. This is the case in our study
as recurrence of AH was observed in two patients out of the
seven studied patients (29%).
Radiographic ﬁndings ranging from diffuse alveolar inﬁl-
trates to lobar inﬁltrates and are not speciﬁc. Similarly, CT
scans and magnetic resonance imaging have been used in PH
but its usefulness, especially in ill patient is limited [28,29].
Several radiographic patterns were seen, probably reﬂecting
the location, extent and duration of AH. Although classically
described as a diffuse bilateral alveolar interstitial ﬁlling pat-
tern, unilateral lobar inﬁltrates have been reported. None of
these radiographic patterns are speciﬁc for AH [24,30]. Radio-
graphic studies in the present work revealed newly encountered
alveolar inﬁltrates in all episodes of AH (100%). The most
common radiographic pattern was bilateral diffuse inﬁltrates
in eight out of nine episodes (89%). Unilateral densities were
seen in one episode. HRCT was performed in four episodes
and revealed diffuse alveolar inﬁltrates.
PH occurred in acutely ill patients with high disease activity
estimated by SLEDAI. It was severe in six patients and mod-
erate in one case of the present study. This agrees with Badsha
et al. [31] as the median SLEDAI and mean SLAM scores were
high and the authors recommended that SLEDAI and SLAM
scores should raise the index of suspicion of PH. However,
Chang et al. [7] results showed SLE activity at presentation
was diverse (SLEDAI range 15–41). They recommended that
the physician should be aware of DAH in SLE patients regard-
less of the disease activity or chronicity. Also, they concluded
that APACHE II (Acute physiology, Age and Chronic Health
Evaluation) and organ system failure (OSF) scores, but not the
SLEDAI, could probably predict the outcome of DAH in
SLE.
Many published series emphasize the simultaneous presence
of DAH with multiple extrapulmonary manifestations of SLE
[15–17,19]. Lupus nephritis was the most common concurrent
systemic ﬁnding in our patients (6/7) (86%). This was concor-
dant with many previous reports [15–17,33]. It has been re-
ported that active nephritis associated with nephrotic
syndrome is the major risk factor for PH in SLE [15]. Nearly,
all our patients had proteinuria and two had nephrotic syn-
drome. Kidney biopsy in our patients revealed diffuse prolifer-
ative GN in four cases, membranous GN in one case and end
stage renal disease (ESRD) in one case. Serum creatinine was
raised in ﬁve out of six patients with renal affection. It was mea-
sured at time of episodes and the range was (3.7–5.7) mg/dl
while before episodes the range was (1.03–7.4) mg/dl. Three pa-
tients with ﬁve episodes needed dialysis and only one required
regular dialysis. Two episodes (2/5) that underwent dialysis sur-
vived the attack and the other three episodes (3/5) did not sur-
vive. On the other hand, Lee et al. [34] reported 7 SLE patients
with DAH. They assumed that azotemia (sCr > 3.0) mg/dl and
hemodialysis therapy had no signiﬁcant association with the in-
creased risk of mortality in their series. Chang et al. [7] reported
that the higher serum creatinine or the need of HD did not ad-
versely affect the survival of his patients also.The second most frequent associated extrapulmonary man-
ifestation was CNS lupus (55.5%). This agrees with Liu et al.
[15] who reported 61% incidence of CNS among his patients.
However, Santos Ocampo et al. [5] reported only 10% inci-
dence of CNS disease. We reported major CNS lupus preced-
ing three episodes of AH which may highlight the possible role
of neurogenic pulmonary edema secondary to CNS lupus as a
possible risk factor in the development of DAH as reported by
Chang et al. [7].
Arthralgia and arthritis were the least extrapulmonary
manifestation associated the AH attacks (11%) in our study.
This may be explained by assumption of Santos Ocampo
et al. [5] who reported that milder SLE manifestations may
have been masked at the time of AH because of ongoing
immunosuppressive therapy (see Table 11).
It is generally believed that treatment of life threatening
hemorrhage needs to be started promptly because death from
respiratory failure can occur within hours to days of initial pre-
sentation [35].
Initial treatment included IV methylprednisolone for 3 days
and IV cyclophosphamide in four episodes while it was given
1 week prior to the attack in two episodes. All patients
required ICU admission. All episodes except two needed to
be supported by mechanical ventilation. The other two episodes
needed only O2 mask.
The aggressive treatment did not appear to affect outcome
in our group of patients. Corticosteroids were the mainstay of
therapy for AH. However, in SLE patients with PH there were
no clear indications about which treatment modality inﬂuence
the outcome. Several authors have recommended the use of
high-dose corticosteroids and cytotoxic agents as well as plas-
mapheresis as soon as the diagnosis of hemorrhage is estab-
lished [23,35–37]. Most series report a very complicated
downhill course in patients with hemorrhage despite aggressive
cytotoxic therapy [16,30,35,38]. No correlation between treat-
ment regimens and response rates has been documented and
death has often been attributed to respiratory failure
[30,33,39,40].
Liu et al. [15] reported that there was no single case of PH
without antecedent aggressive corticosteroid treatment and
suggested the possibility that high dose corticosteroid therapy
itself poses an increase risk of PH in SLE patients. The authors
attributed this to connective tissue atrophy resulting from pro-
longed usage of steroid.
Badsha et al. [31] suggests that increased use of cyclophos-
phamide may confer a survival beneﬁt. However, Zamora
et al. [17] used cyclophosphamide in the majority of their pa-
tients and the mortality rate was increased for these receiving
cyclophosphamide and they argue that if it is used in an acute
episode it contributed to mortality. Based on Cooper et al. [41]
assumption that cyclophosphamide could cause hemorrhagic
pneumonitis Wu et al. [42] suggested that cyclophosphamide
should be used carefully in SLE patients with PH.
In the present study, we reported a poor prognosis with
14% survival. However, there have been some controversies
regarding survival rates following attaches of AH in SLE.
The highest survival rates have been reported by Schwab
et al. [19] and Santos Ocampo et al. [5] with 75% and 100%
survival rates, respectively. The lowest survival rate was re-
ported by Abud Mendoza et al. [16] with 8%. Also Liu et al.
[15] 23% and Barile et al. [20] 38% showed low survival rates.
Table 11 Characteristics and clinical presentation of patients with SLE-associated AH (current and selected case series from 1985 to present).
Variables Current Badsha
et al. [31]
Santos
Ocampo et al. [5]
Liu et al. [15] Barile et al.
[20]
Koh et al.
[14]
Zamora et al. [17] Schwab et al.
[19]
Myers and
Katzenstein [13]
Abud
Mendoza et al. [16]
Patient characteristics
Patients, no. 7 22 7 13 34 10 15 8 4 12
% of SLE cohort 1.3 1.4 1 4 5.4 1.4 3.7 1.4 – 1.6
Male/female, no. 0/7 2/22 1/6 1/12 2/32 2/8 5/10 2/6 3/1 0/12
Mean age, years 23 31.6 31.1 26 34.5 26.5 30.1 37.8 29 23
Range, years 17–35 – 19–44 10–50 – 13–44 19–44 17–54 13–51 16–40
Mean duration of
SLE, years
2 0.96 4.5 1.9 14.1 1.8 2.5 2.3 – 2
Range, years 4 months–4 years – 2 weeks–19 years 4 weeks–5 years – 0–5 0–8 0.1–7 – 0.1–5
(+) Anti-ds DNA, % 100 – 43 61 88 50 – 87.5 75 25
Presenting signs and symptoms of AH, % of episodes
Hemoptysis 100 50 50 84 58 30 42 100 75 25
New inﬁltrates 100 100 100 100 100 100 100 87 100 83
Alveolo-interstitial – – 80 – – 100 100 – 100 83
Lobar – – 20 – – 0 0 12 0 –
Bilateral 89 – 80 100 – – 100 – 100 –
Unilateral 11 – 20 – – – 0 12 0 –
Pleural eﬀusions 22 – 30 – – – 37 – – –
Anemia 100 100 90 100 91 100 94 75 – 100
Dyspnea 89 – 100 100 100 – – 73 87
Fever 67 – 80 54 – 90 26 100 25 25
Chest pain – – 30 – – 20 – – – –
Extrapulmonary signs and symptoms accompanying AH, % of episodes
Renal-nephritis 86 77 70 100 32 40 93 62 – 41
Hematologic
Leukopenia 22 32 30 23 – 20 0 – – 50
Thrombocytopenia 0 40 20 61 – – 31 – – –
AIHA 0 – – – – – – – – –
Skin-mucositis 0 68 0 38 47 70 73 62 – 41
Arthralgia–arthritis 11 68 10 15 44 30 15 62 – 16
Neuro-psychiatric
lupus
55.5 32 10 61 14 20 47 37 – 58
Low complements 86 91 83 84 – 70 – 100 75 25
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10 G.A. Mahmoud et al.In contrast to poor prognosis shown in most reports,
including ours, Schwab et al. [19] had shown optimistic results
in their SLE patients with pulmonary hemorrhage. The expla-
nation of these contradictory results may be difﬁcult. How-
ever, different subsets of patients with PH are the most likely
reason for the different outcome.
The prognosis is poor in SLE patient with PH. Zamora
et al. [17] described that factors associated with increased mor-
tality include mechanical ventilation. This may explain the
poor prognosis in our study as mechanical ventilation was ap-
plied in (7/9) episodes and it was associated with high mortal-
ity (6/7) (86%) compared with no deaths in the two episodes in
which mechanical ventilation was not employed.
Finally, PH is a rare but lethal complication of SLE and
represents a remarkable challenge. It should be diagnosed
promptly in the SLE patient with falling red cell indices and
new inﬁltrates on chest radiograph. It occurs in vicinity of ac-
tive disease and lupus nephritis is the most associated manifes-
tation. Early treatment with IV methylprednisolone and IV
cyclophosphamide should be instituted for a better outcome
(see Table 12).
Our conclusion is that DAH is a serious manifestation and
it should be a part of the differential diagnosis in all SLE pa-
tients presenting with hemoptysis and lung inﬁltrates. In ab-
sence of hemoptysis, diffuse pulmonary inﬁltrates, falling
hemoglobin and hemorrhagic BAL conﬁrm the diagnosis.
Early recognition and aggressive therapy needs to be started
promptly because death from respiratory failure can occur
within hours to days of initial presentation.References
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